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Angiotensin-II (Ang-II) type 1 (AT1) receptor blockers may
delay the progression of chronic allograft nephropathy
(CAN). However, neither the optimal time for initiating AT1
receptor blockade in order to delay CAN potentially nor the
role of Ang-II type 2 (AT2) receptors under AT1 receptor
blockade is known. Both AT receptors can regulate p53
expression and apoptosis. We investigated what time of
initiation with AT1 blockers most effectively delayed CAN as
well as the role of the AT2 receptor, and how angiotensin
receptor blockade affected apoptosis and its regulating
factors in this context in a rat model. Kidneys of Fisher (F344)
rats were transplanted into Lewis rats. Animals were treated
with AT1 (candesartan) and/or AT2 (PD123319) receptor
antagonists, a calcium channel blocker, or vehicle (treatment
periods: day 7 before to week 24 after transplantation (long
term), week 12 to week 24 (late), day 7 to day þ 5 (early))
and observed the animals for 24 weeks. Reduction of
proteinuria, grade of CAN, and number of apoptotic cells was
most pronounced in animals receiving long-term AT1
receptor blockade. A combined AT1/AT2 blocker treatment
reduced CAN similarly to AT1 blocker treatment alone. The
number of apoptotic cells and the level of p53 mRNA were
significantly lower in long-term AT1 blocker-treated animals.
In summary, AT1 receptor blockade delayed the progression
of CAN, particularly in animals treated long term. Reduction
of apoptosis could be related to these beneficial effects. The
AT2 receptor does not appear to play an important role in
CAN.
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Chronic allograft nephropathy (CAN), a major cause of late
allograft failure, is characterized by glomerulopathy, tubular
atrophy, interstitial fibrosis, and vasculopathy.1,2 The initial
graft damage is mediated by ischemia/reperfusion, surgical
trauma, and alloantigen-related factors, thus influencing the
development and progression of CAN.3,4
Inhibition of the renin–angiotensin system by angiotensin-
converting enzyme inhibitors5 and Angiotensin-II (Ang-II)
type 1 (AT1) receptor blockers
6 ameliorates the progression
of chronic renal diseases including CAN.7 However, the
optimal time point for the initiation of AT1 receptor blockade
to achieve the best amelioration of long-term graft function is
as unknown as the contribution of the AT1 and the Ang-II
type 2 (AT2) receptors in this context.
Among other effects, signalling via the AT1 receptor
increases blood pressure, and promotes cellular proliferation
as well as extracellular matrix production, thus contributing
to the progression of fibrosis. The role of the AT2 receptor on
the other hand, which could be involved in antiproliferative,
antiangiogenic, and blood pressure lowering effects during
the development of CAN, is not yet clear. Thus, the
amelioration of fibrosis in CAN by AT1 receptor blockade
may also depend on signalling via non-blocked AT2
receptors.
Furthermore, the mechanisms involved in the protective
effects of AT1 receptor blockade are not fully understood.
Apart from reduced proteinuria and proliferation, a
reduced number of apoptotic cells in the graft may be
related to the amelioration of CAN by AT1 receptor
antagonists. Apoptosis is an intrinsically controlled process
of cellular suicide8 and can significantly contribute to tissue
damage by a reduction of functioning kidney cells.9 An
increased number of apoptotic cells has been described in
human graft biopsies with CAN,10 whereas a reduced
expression of cytoprotective factors together with an
increased number of apoptotic cells has been observed in a
rat model of CAN.11 Interestingly, apoptosis can be induced
by Ang-II via both AT1
12,13 and AT2
14–16 receptors in various
cell types, including renal tubular cells.17,18 These divergent
results could be related to different cell types and treatment
conditions.
How Ang-II influences apoptosis is not fully understood.
A potential factor involved in Ang-II-mediated apoptosis is
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p53, which can result in cell cycle arrest and/or apoptosis.19
Stimulation of AT1 receptors increased p53 in parallel to the
number of apoptotic cells in a model of stretch-induced stress
in myocytes.20 AT1 and AT2 receptors have been reported to
stimulate p53 DNA binding or p53 expression, respectively,
together with an upregulation of the apoptosis-promoting
Bax protein.21,22
Here, we analyzed the effects of AT1 and AT2 receptor
blockade over different periods after kidney transplantation
on the progression of CAN, the role of the AT2 receptor
during CAN, and how AT receptor blockade influences
apoptosis and the expression of p53 as a possible link
between Ang-II and apoptosis regulation.
RESULTS
Long-term treatment with an AT1 receptor antagonist
resulted in reduced proteinuria and morphological changes
of CAN
Proteinuria and creatinine clearances 24 weeks after
transplantation. Animals receiving long-term AT1- (AT1)
and combined AT1/AT2 antagonist treatment (AT1þAT2)
developed a significantly lower proteinuria than animals
receiving AT2 antagonist- (AT2) and vehicle (VEH) treatment
(Pp0.03; Figure 1a), whereas proteinuria tended to be lower
as compared to animals treated with a calcium channel
blocker (CCB) (P¼ 0.06 and 0.11). Animals receiving late
and early treatment developed no statistically significant
differences (P40.05; Figure 1b and c), although animals
receiving late AT1- (AT1) and combined AT1-/AT2 antagonist
treatment (AT1þAT2) had lower proteinuria as animals of
groups AT2, CCB, and VEH.
Creatinine clearances as well as mean arterial pressure and
body weights did not differ significantly between the groups
at week 24 (Table 1).
One animal of each group AT1, AT2, and VEH receiving
long-term treatment died owing to surgical complications;
one animal of group VEH died after week 12.
One animal of group AT1 receiving late treatment died
after surgery. One animal from each group AT1, AT2, and
AT1þAT2 died after 20 weeks.
One animal of group AT2 receiving early treatment died
after 12 and 20 weeks, respectively.
Grade of CAN. Animals of long-term treatment group AT1
or group AT1þAT2 developed a significantly lower grade of
CAN as compared to the groups AT2, CCB, and VEH
(Po0.05; Figure 2a). Animals treated late or early did not
significantly differ in the grade of CAN. However, animals
receiving late treatment of groups AT1 as well as group
AT1þAT2 had, although not significant, lower grades of
CAN (P40.05; Figure 2b and c).
Glomerulosclerosis. Glomerulosclerosis was significantly
lower in animals treated long term with the AT1 receptor
antagonist as compared to groups AT2, CCB, and VEH
(Pp0.012; Table 1, Figure 3a). Animals of group AT1þAT2
had a lower glomerulosclerosis as compared to the groups
AT2, CCB, and VEH (Pp0.025). Glomerulosclerosis in
animals receiving late and early treatment did not signifi-
cantly differ, although, again, late treatment in groups AT1
and AT1þAT2 resulted in a lower glomerulosclerosis as
compared to the groups AT2, CCB, and VEH (P40.05;
Table 1).
Macrophage infiltration of the graft. Animals of long-term
treatment group AT1 had a significantly reduced number of
macrophages in graft tissues as compared to group AT2
(P¼ 0.01). Macrophage infiltration was also lower as
compared to groups CCB and VEH (Po0.03; Table 1).
Animals of group AT1þAT2 had a significantly reduced
macrophage infiltration as compared to groups AT2, CCB,
and VEH (Po0.01). Late and early treatment resulted in no
Weeks after transplantation
0 8 12 16 20 24
Pr
ot
ei
nu
ria
 (m
g/k
g/d
ay
)
2
4
6
8
10
12
14
16
Weeks after transplantation
8 12 16 20 24
Pr
ot
ei
nu
ria
 (m
g/k
g/d
ay
)
0
2
4
6
8
10
12
14
16
Weeks after transplantation
4 8 12 16 20 24
Pr
ot
ei
nu
ria
 (m
g/d
ay
/bw
)
0
2
4
6
8
10
12
14
16
*
**
4
4
a
c
b
Figure 1 | Proteinuria 24 weeks after transplantation.
(a) Proteinuria in animals treated long term from day 7 before
transplantation to week 24 after transplantation was significantly
lower in animals of groups AT1 and AT1þAT2 as compared to
groups AT2 and VEH (*AT1 vs AT2: P¼ 0.03; vs CCB: P¼ 0.06; vs VEH:
P¼ 0.03. **AT1þAT2 vs AT2: P¼ 0.006; vs CCB: P¼ 0.11; vs VEH:
P¼ 0.024). (b) Proteinuria in animals treated late from week 12 to
week 24 after transplantation was lowest in animals of groups AT1
and AT1þAT2. However, the differences were not statistically
significant (*P40.05). (c) Animals treated early from day 7 before
transplantation to day 5 after transplantation had no significantly
different proteinuria (P40.05).K¼AT1: treatment with AT1 receptor
antagonist; J¼AT2: treatment with AT2 receptor antagonist;
.¼AT1þAT2: treatment with AT1 and AT2 receptor antagonist;
,¼CCB: treatment with CCB; and ’¼VEH: treatment with vehicle.
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significant differences. However, animals of late treatment
group AT1 and AT1þAT2 had a reduced number of graft-
infiltrating macrophages as compared to groups AT2, CCB,
and VEH, (P40.05; Table 1).
Number of proliferating cells. The number of proliferating
cells did not differ significantly between the experimental
groups at the end of the observation period 24 weeks after
transplantation (Table 1).
Long-term treatment with an AT1 receptor antagonist
reduced the number of apoptotic cells
Number of apoptotic cells. Animals of long-term treat-
ment groups AT1 and AT1þAT2 had a significantly lower
number of apoptotic cells in their grafts as compared
to animals of group AT2 and VEH (Pp0.03; Figures
3b and 4a).
The number of apoptotic cells in grafts of animals of late
and early treatment groups AT1 or AT1þAT2 were not
significantly different as compared to groups AT2, CCB, and
VEH (P40.05; Figure 4b and c).
Levels of mRNA of apoptosis-related factors bcl-2/bax mRNA
ratio. The lower number of apoptotic cells in animals of
long-term treatment group AT1 was paralleled by a significant
shift of the mRNA ratio of bcl-2/bax towards bcl-2 mRNA
(coding for apoptosis-inhibiting Bcl-2) in group AT1 as
compared to groups AT2 (P¼ 0.045) and VEH (P¼ 0.012),
as well as group AT1þAT2 as compared to group VEH
(P¼ 0.018; Figure 5a).
Table 1 | Body weight (g; mean7s.e.m.), MAP (mm Hg; mean7s.e.m.), and creatinine clearance (ml/min; mean7s.e.m.)
Group AT1 AT2 AT1+AT2 CCB VEH
Long-term treatment (n) 7 7 8 8 6
Body weight (g) 480.6719.9 474.0712.6 488.879.6 488.079.7 497.579.8
MAP (mm Hg) 92.673.9 95.276.6 86.774.1 89.876.4 92.576.6
Creatinine clearance (ml/min/kg) 4.0170.37 4.0970.36 4.0270.43 4.6670.55 3.7870.24
Glomerulosclerosis (%) 11.571.31 24.571.8 16.571.411 27.572.0 27.771.6
Grade of macrophage infiltration ~ ~~
0 5 — 4 — —
Grade 1 2 1 4 4 1
Grade 2 — 4 — 2 2
Grade 3 — 2 — 2 3
PCNA (cells/field of view) 4.970.6 5.570.8 5.771.1 4.170.5 4.570.5
Late treatment (n) 6 7 7 8 8
Body weight (g) 467.0720.2 472.579.4 474.3719.4 479.376.3 479.1711.9
MAP (mm Hg) 93.778.1 91.377.1 88.875.8 94.878.5 95.475.9
Creatinine clearance (ml/min/kg) 4.0270.34 4.1770.41 3.6770.36 3.6770.95 4.1870.22
Glomerulosclerosis (%) 18.572.4 23.473.1 18.171.7 21.172.1 22.171.5
Grade of macrophage infiltration
0 3 — 3 1 1
Grade 1 2 2 3 3 3
Grade 2 1 3 1 3 2
Grade 3 — 2 — 1 2
PCNA (cells/field of view) 4.272.2 4.171.8 4.970.8 4.470.7 4.072.4
Early treatment (n) 6 4 6 6 6
Body weight (g) 472.0713.5 482.5718.3 484.778.5 486.779.0 460.5716.6
MAP (mm Hg) 94.774.2 94.0710.1 91.674.8 91.078.8 93.676.9
Creatinine clearance (ml/min/kg) 4.2370.3 4.1270.33 3.7870.22 3.8570.38 4.0170.24
Glomerulosclerosis (%) 23.673.1 25.873.3 27.473.2 25.673.9 22.972.1
Grade of macrophage infiltration
0 1 — 2 1 1
Grade 1 2 1 2 3 2
Grade 2 1 2 2 2 2
Grade 3 2 1 — — 1
PCNA (cells/field of view) 4.971.0 5.971.4 5.070.9 5.770.7 5.070.4
AT1, Angiotensin-II type 1; AT2, Angiotensin-II type 2; CCB, calcium channel blocker; MAP, mean arterial pressure; PCNA, proliferating cell nuclear antigen; VEH, vehicle.
Glomerulosclerosis of graft tissue of the experimental groups: long-term treatment: 1P=0.006 vs AT2, P=0.006 vs CCB, and P=0.012 vs VEH; 11P=0.012 vs AT2, P=0.012 vs CCB,
and P=0.024 vs VEH. Late and early treatment: P40.05 AT1 and AT1+AT2 vs AT2, CCB, and VEH.
Grade of infiltration by macrophages (CD68 positive cells): 0=o5 cells/field of view; grade 1=6–25 cells/field of view; grade 2=26–50 cells/field of view; and grade 3=450
cells/field of view. Numbers represent number of cases with the respective grade of infiltration: Long-term treatment: ~P=0.01 vs AT2, P=0.028 vs CCB, and P=0.016 vs VEH;
~~P=0.008 vs AT2, P=0.006 vs CCB, and P=0.013 vs VEH. Late and early treatment: P40.05 AT1 and AT1+AT2 vs AT2, CCB, and VEH.
Number of proliferating cells (PCNA) (cells/field of view; mean7s.e.m.).
Long-term treatment (day 7 to week 24), late treatment (week 12 to week 24), and early treatment (day 7 to day +5); n=number of animals analyzed 24 weeks after
transplantation.
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A significant shift of the mRNA ratio of bcl-2/bax towards
bcl-2 mRNA was observed in animals of late treatment
groups AT1 and AT1þAT2 (Po0.01; Figure 5b), whereas
early treatment resulted in no significant differences as
compared to controls (P40.05; Figure 5c).
p53 levels. Animals of long-term treatment group AT1
had significantly lower p53 levels as compared to animals of
groups AT2 (P¼ 0.03) and VEH (P¼ 0.06; Figure 6a). Late
and early treatment resulted in no significant differences in
the expression of p53 (P40.05; Figure 6b and c).
Caspase-1 and caspase-3 mRNA levels. Animals of long-
term treatment group AT1 had significantly lower levels of
caspase-1 and caspase-3 mRNA as compared to animals of
groups AT2 and VEH (Pp0.03; Figures 7a and 8a). Animals
of group AT1þAT2 had significantly reduced caspase-3
mRNA levels as compared to animals of groups CCB and
VEH (P¼ 0.03; Figure 7a), whereas caspase-1 mRNA levels
were significantly lower as compared to animals of group
VEH (P¼ 0.012; Figure 8a).
Animals of late treatment group AT1 had significantly
lower caspase-1 and caspase-3 mRNA levels as compared to
animals of group VEH (Po0.01; Figures 7b and 8b).
Late combined AT1 and AT2 receptor antagonist treatment
resulted in significantly lower caspase-1 mRNA levels as
compared to animals of groups AT2 and VEH (P¼ 0.03;
Figure 8b).
Animals receiving early treatment developed no significant
differences (Figures 7c and 8c).
DISCUSSION
In our model of CAN, AT1 receptor blockade reduced
proteinuria, grade of CAN, and glomerulosclerosis as
compared to animals receiving AT2 receptor blockade and
controls receiving VEH treatment. The beneficial effects of
AT1 receptor blockade were most obvious in animals treated
for the entire period as compared to animals receiving late
AT1 antagonist treatment. Although creatinine clearances did
not differ between the experimental groups, after a longer
follow-up, a significant difference could be expected between
the groups in this experimental model as development of
proteinuria usually precedes a drop in glomerular filtration
rate.
These results are in congruence with observations that
inhibition of the renin–angiotensin system by angiotensin
converting enzyme inhibition limits CAN even when
treatment was delayed.23 Although we also observed a
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Figure 2 | Chronic allograft nephropathy. (a) Grade of CAN in
animals treated long term from day 7 before transplantation to
week 24 after transplantation was significantly lower in animals of
groups AT1 and AT1þAT2 as compared to the other groups (*AT1 vs
AT2: P¼ 0.028; vs CCB: P¼ 0.024; vs VEH: P¼ 0.031. **AT1þAT2 vs
AT2: P¼ 0.031; vs CCB: P¼ 0.029; vs VEH: P¼ 0.03). (b) Grade of CAN
in animals treated late from week 12 to week 24 after transplantation
tended to be lower in animals of groups AT1 and AT1þAT2 as
compared to the other groups (P40.05). (c) Grade of CAN in animals
treated early from day 7 before transplantation to day 5 after
transplantation did not significantly differ between the groups
(P40.05). Grade of CAN: &¼mild, ¼moderate, and ’¼ severe.
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Figure 3 | Histology of kidney grafts. (a) Normal tubuli and
glomeruli in animals of group AT1 (long term); (b) interstitial fibrosis,
tubular atrophy, glomerulosclerosis, and inflammatory infiltrates in
long-term control animals (VEH) (a and b periodic acid-Schiff
(PAS) reaction, original maginification  100); small artery with
hypertrophy and hyperplasia of the intima and media (PAS reaction,
original magnification  400) (see inset). (c) Apoptotic tubular
cells in graft tissue of animals receiving long-term AT1 antagonist
treatment (AT1) (original magnification  400); (d) TUNEL-positive
tubular cells in graft tissue of long-term controls (VEH) (original
magnification  400). Apoptosis primarily affected tubular epithelial
cells of the proximal and distal tubules within the cortex as well
as within nephron segments of the medulla.
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reduction in proteinuria and grade of CAN in animals with
delayed treatment, this effect was less pronounced in our
experiment. The differences can be explained by use of an
AT1 receptor antagonist, the shorter follow-up time, and a
lower cyclosporin A dose in our series.
Whether AT2 receptors, whose expression increases under
pathological conditions,24 contribute to the beneficial effects
after the blockade of AT1 receptors in delaying CAN is not
known. Some groups suggested that signalling via the AT2
receptor mediates the beneficial effects associated with the
blockade of AT1 receptors as AT2 receptor knockout mice
developed a more severe fibrosis as compared to AT1 receptor
knockout and wild-type mice in a model of interstitial
fibrosis.25 Similarly, it has been suggested that high levels of
Ang-II following AT1 receptor blockade stimulate non-
engaged AT2 receptors, and thereby influence extracellular
matrix turnover, which may explain the decreased fibrosis
observed in a rat model of ischemic myocardial fibrosis.26
Contrary to these observations, in our experiment the
protective effect of long-term AT1 receptor blockade even in
the presence of additional AT2 receptor blockade suggested
that signalling via the AT2 receptor is not of crucial
importance for the delay of CAN. The differences between
the models may be explained by variations in the expression
of the two receptor subtypes with regard to tissue type, cell
type, disease stage as well as the quality of receptor cross-talk.
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Figure 4 | TUNEL-positive apoptotic cells. (a) TUNEL-positive
apoptotic cells in animals treated long term from day 7 before
transplantation to week 24 after transplantation were significantly
lower in animals of group AT1 and group AT1þAT2 as compared to
groups AT2 and VEH (*AT1 vs AT2: P¼ 0.027; vs CCB: P¼ 0.12; vs VEH:
P¼ 0.03. **AT1þAT2 vs AT2: P¼ 0.015; vs CCB: P¼ 0.12; vs VEH:
P¼ 0.03). (b) Apoptotic cells in animals treated late from week 12 to
week 24 after transplantation tended to be lower in animals of group
AT1 and AT1þAT2 as compared to the other groups (P40.05).
(c) The number of apoptotic cells in animals treated early from day
7 before transplantation to day 5 after transplantation did not differ
significantly between the groups (P40.05). &¼AT1: treatment with
AT1 receptor antagonist; ¼AT2: treatment with AT2 receptor
antagonist; ¼AT1þAT2: treatment with AT1 and AT2 receptor
antagonist; ¼CCB: treatment with CCB; and ’¼VEH: treatment
with vehicle.
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Figure 5 | Ratio of bcl-2/bax mRNA levels. (a) Animals receiving
long-term AT1 antagonist treatment (group AT1) from day 7 before
transplantation to week 24 after transplantation had a significantly
shifted ratio toward bcl-2 mRNA as compared to animals of groups
AT2 and VEH (*AT1 vs AT2: P¼ 0.045; vs CCB: P¼ 0.27; vs VEH:
P¼ 0.012). Animals of group AT1þAT2 had a ratio, which was
significantly shifted to bcl-2 mRNA as compared to group VEH
(**AT1þAT2 vs AT2: P¼ 0.06; vs CCB: P40.05; vs VEH: P¼ 0.018).
(b) Animals receiving late (week 12 to week 24 after transplantation)
AT1 antagonist treatment (group AT1) and AT1þAT2 antagonist
treatment (group AT1þAT2) had a ratio shifted towards bcl-2 mRNA
as compared to animals of groups AT2, CCB, and VEH (*AT1 vs AT2:
P¼ 0.006; vs CCB: P¼ 0.006; vs VEH: P¼ 0.003. **AT1þAT2 vs AT2:
P¼ 0.018; vs CCB: P¼ 0.03; vs VEH: P¼ 0.009). (c) The ratios in animals
receiving early treatment from day 7 before transplantation to day
5 after transplantation did not significantly differ between the groups
(P40.05). &¼AT1: treatment with AT1 receptor antagonist;
¼AT2: treatment with AT2 receptor antagonist; ¼AT1þAT2:
treatment with AT1 and AT2 receptor antagonist; ¼CCB: treatment
with CCB; and ’¼VEH: treatment with vehicle.
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In accordance with our results are observations that AT1
receptor-activating antibodies can promote vascular rejec-
tions that may eventually contribute to the progression of
CAN.27
How did AT1 receptor blockade delay the progression of
CAN, particularly in the long-term-treated animals? Low-
ering blood pressure alone was not responsible for the
favorable results of AT1 receptor blockade as blood pressure
did not significantly differ between the groups, which is in
congruence with previous reports.28,29
Apoptosis might contribute to a decrease of graft function
by a reduction of functioning nephrons. Interestingly, Ang-II
can induce apoptosis in tubular epithelial cells through the
AT1
30 as well as the AT2 receptor.
31 Thus, angiotensin
receptor blockers could exert their protective effects also via
an inhibition of apoptosis. Interestingly, Cao et al.32 observed
an inhibition of apoptosis, together with a protective effect,
by the AT2 receptor antagonist PD123319 in a model of
subtotal nephrectomy. In another experiment, apoptosis of
tubular cells was inhibited by an AT2 receptor blocker in a
short-term model of obstructive nephropathy.22
In our experiments, the lower proteinuria and grade
of CAN was paralleled by a lower number of apoptotic
tubular cells and a shift of the ratio of bcl-2/bax mRNA
levels toward the antiapoptotic Bcl-2 in parallel to reduced
caspase-3 mRNA levels (coding for caspase-3 that belongs
to the effector molecules of apoptosis) in animals treated
with the AT1 receptor antagonist over the long term as
compared to AT2 receptor antagonist-treated animals and
VEH-treated controls. Although mRNA levels should
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Figure 6 | Expression of p53. (a) Animals receiving long-term (day
7 before transplantation to week 24 after transplantation) AT1
antagonist treatment (group AT1) had a significantly lower p53
expression as compared to animals of groups AT2 and VEH (*AT1 vs
AT2: P¼ 0.03; vs CCB: P40.05; vs VEH: P¼ 0.06. **AT1þAT2 vs AT2,
CCB, VEH: P40.05). (b) Animals receiving late (week 12 to week 24
after transplantation) AT1 and AT1þAT2 antagonist treatment
(groups AT1 and AT1þAT2) had a lower expression as compared to
animals of groups AT2, CCB, and VEH, respectively, but the
differences were not significant (P40.05). (c) Animals receiving
early treatment (day 7 before transplantation to day 5 after
transplantation) had no significant differences between the
groups (P40.05). &¼AT1: treatment with AT1 receptor
antagonist; ¼AT2: treatment with AT2 receptor antagonist;
¼AT1þAT2: treatment with AT1 and AT2 receptor antagonist;
¼CCB: treatment with CCB; and ’¼VEH: treatment with
vehicle.
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Figure 7 | Caspase-3 mRNA. (a) Animals receiving long-term (day 7
before transplantation to week 24 after transplantation) AT1
antagonist treatment (group AT1) had significantly lower levels of
caspase-3 mRNA as compared to groups AT2 and VEH (*AT1 vs AT2:
P¼ 0.018; vs CCB: P¼ 0.09; vs VEH: P¼ 0.018). Animals of group
AT1þAT2 had significantly lower levels as compared to groups CCB
and VEH (**AT1þAT2 vs AT2: P¼ 0.06; vs CCB: P¼ 0.03; vs VEH:
P¼ 0.03). (b) Animals receiving late (week 12 to week 24 after
transplantation) AT1 antagonist treatment (group AT1) had
significantly lower caspase-3 mRNA levels as compared to animals
of groups CCB and VEH (*AT1 vs AT2: P¼ 0.09; vs CCB: P¼ 0.009;
vs VEH: P¼ 0.006. **AT1þAT2 vs AT2: P¼ 0.15; vs CCB: P¼ 0.09; vs
VEH: P¼ 0.12). (c) Animals receiving early treatment (day 7 before
transplantation to day 5 after transplantation) had no significant
differences (P40.05). &¼AT1: treatment with AT1 receptor
antagonist; ¼AT2: treatment with AT2 receptor antagonist;
¼AT1þAT2: treatment with AT1 and AT2 receptor antagonist;
¼CCB: treatment with CCB; and ’¼VEH: treatment with vehicle.
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be cautiously interpreted with respect to protein expression,
the mRNA data in our model paralleled the number of
apoptotic cells in the grafts. Thus, in our model, the AT1
receptor seems to influence apoptosis more as compared to
the AT2 receptor.
However, whether apoptosis is involved in the pathogen-
esis of CAN is not clear so far. Data supporting a pathogenic
role of apoptosis for renal tissue damage is derived from
ischemia/reperfusion experiments, where inhibition of apop-
tosis protected kidneys from acute ischemia/reperfusion
injury.33 In kidney transplantation, observational studies
have related apoptosis to CAN.10 In models of unilateral
ureteral obstruction, cell compartment-specific as well as
time-dependent effects seem to influence apoptosis with
different effects regarding interstitial volume or tubular
atrophy for example.34
In our series, long-term AT1 receptor blockade was
associated with a reduced number of apoptotic cells and an
amelioration of CAN, whereas the effects of late AT1 receptor
blockade on apoptosis and CAN were not significant. On the
other hand, our group previously showed that late adminis-
tration of the mammalian target of rapamycin inhibitor
everolimus, known to induce apoptosis in immune cells and
activated non-immune cells, also ameliorated CAN, which
was associated with an increased number of apoptotic cells.35
Conversely in a model of renal ischemia/reperfusion, early
administration of the mammalian target of rapamycin
inhibitor sirolimus also increased the number of apoptotic
cells, but augmented renal damage.36 It is difficult to compare
the results of different studies as observation times, dosing of
the drugs, and potential different effects of the drugs on
apoptosis related to the type of the cell and its proliferation
status might influence the overall effect. Further studies are
needed to clarify what role apoptosis plays in progressive
renal diseases and whether apoptosis could also be associated
with varying effects at different periods during their
progression.
In our study, the differences in the number of apoptotic
cells were probably not related to cellular proliferation in the
graft tissues, as no significant differences in the number of
proliferating cells were present.
Interestingly, animals receiving long-term AT1 receptor
antagonist treatment had lower caspase-1 mRNA levels
together with a reduced macrophage infiltration of the graft
tissue as compared to controls. As caspase-1 has been
associated with apoptosis37 and inflammation,38 a link
between those processes may exist. Thus, hypothetically,
the function of caspase-1 (apoptotic/inflammatory) could
depend on the surrounding environment.
What could be the mechanisms responsible for a
reduction of apoptosis by inhibition of the AT1 receptor?
One of the pathways by which Ang-II can induce apoptosis is
an upregulation of p53 that in turn can increase the number
of AT1 receptor molecules, and, moreover, shifts the Bcl-2/
Bax ratio toward the apoptosis-promoting Bax.21,39. This is
supported by our findings in animals receiving long-term
AT1 receptor blockade, as these animals had a reduced
expression of p53 as compared to AT2 receptor antagonist-
treated animals.
Apart from a direct effect on the reduction of apoptosis in
the grafts, indirect effects such as a decrease in proteinuria
may also have accounted for the beneficial effects of AT1
receptor blockade, as proteinuria is known to induce
apoptosis.40 Thus, it cannot be excluded that the number
of apoptotic cells has additionally been affected through a
reduction of proteinuria as a result of AT1 receptor antagonist
treatment.
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Figure 8 | Caspase-1 mRNA. (a) Animals receiving long-term (day 7
before transplantation to week 24 after transplantation) AT1
antagonist treatment (group AT1) had significantly lower levels of
caspase-1 mRNA as compared to groups AT2, CCB, and VEH (*AT1 vs
AT2: P¼ 0.027; vs CCB: P¼ 0.024; vs VEH: P¼ 0.012. **AT1þAT2 vs
AT2: P¼ 0.14; vs CCB: P¼ 0.09; vs VEH: P¼ 0.012). (b) Animals
receiving late (week 12 to week 24 after transplantation) AT1 and
AT1þAT2 antagonist treatment (groups AT1 and AT1þAT2) had
significantly lower levels of caspase-1 mRNA as compared to groups
AT2, and VEH (*AT1 vs AT2: P¼ 0.03; vs CCB: P¼ 0.15; vs VEH:
P¼ 0.03. **AT1þAT2 vs AT2: P¼ 0.03; vs CCB: P¼ 0.09; vs VEH:
P¼ 0.03). (c) Animals receiving early treatment (day 7 before
transplantation to day 5 after transplantation) had no significant
differences, although levels were higher in animals of group VEH as
compared to the other groups (P40.05). &¼AT1: treatment with
AT1 receptor antagonist; ¼AT2: treatment with AT2 receptor
antagonist; ¼AT1þAT2: treatment with AT1 and AT2 receptor
antagonist; ¼CCB: treatment with CCB; and ’¼VEH: treatment
with vehicle.
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In summary, long-term AT1 receptor blockade delayed
CAN more effectively as late AT1 receptor blockade, while
AT1 receptor signalling seems to be more important than
signalling via the AT2 receptor. Clinical trials are needed to
analyze whether an early initiation of AT1 receptor blockade
could delay CAN in humans more effectively than delayed
blockade. The protective effects of AT1 receptor blockade may
be related to a lower number of apoptotic tubular epithelial
cells in the graft related to the lower expression of p53.
MATERIALS AND METHODS
Animals, surgery, and treatment
Kidneys of male Fisher rats (F344, RT1lvl) (170–210 g) (Charles
River, Sulzfeld, Germany) were transplanted into male Lewis rats
(LEW, RT11) (170–210 g) (Charles River, Sulzfeld, Germany).41 The
left native recipient kidney was removed and the left donor kidney
was orthotopically transplanted by end-to-end anastomosis of renal
artery, vein, and ureter under inhalative anesthesia with isoflurane.
All animals received cyclosporin A subcutaneously (1.5 mg/kg/day;
Sigma-Aldrich, Taufkirchen, Germany) from day 0 to 10 after
transplantation, when the remaining right kidney was removed.
Animals received no other immunosuppressive drugs (e.g. steroids).
We assigned animals to five groups (Table 1): AT1 (AT1 receptor
antagonist candesartan, 5 mg/kg/day); AT2 (AT2 receptor antagonist
PD123319, 1.5 mg/kg/day); AT1þAT2 (candesartan and
PD123319); the control groups received either vehicle (VEH) or
the calcium channel blocker (CCB) lacidipine (1 mg/kg/day) to
control for the potential blood pressure lowering effect of
candesartan.
The different treatments were applied for various periods: long-
term treatment (day 7 to week 24 after transplantation; n¼ 8/
group); late treatment (week 12–24 after transplantation; n¼ 8/
group), and early treatment (day 7 to day 5 after transplantation;
n¼ 6/group). The observation ended after 24 weeks. In the
respective groups, administration of the substances was initiated 7
days before transplantation in donors and recipients to achieve the
maximum pharmacodynamic effect at transplantation.
Functional measurements
We determined 24-h urine protein excretion every 4 weeks.41 Serum
creatinine levels were analyzed by an automatic laboratory analyzer
(Synchron CX5, Beckman Coulter, Krefeld, Germany). Creatinine
clearance was calculated according to the formula (CrCl¼Ucrea
(mg/dl)*diuresis (ml)/Screa (mg/dl)*1440 (min)/weight (kg)). Mean
arterial blood pressure was measured intra-arterially before the
removal of the graft by a digital analyzer using a pressure transducer
(Siemens, Munich, Germany). Measurement was performed under
standard conditions at 241C room temperature between 0900 and
1200 hours.
Morphological studies
Paraffin-embedded tissue sections were stained with hematoxylin
and eosin to evaluate tubulointerstitial fibrosis, vasculopathy, and
tubular atrophy. CAN was graded according to parameters adapted
from the BANFF 97 classification:2 0¼ no signs of CAN; grade
1¼mild CAN (mild fibrosis and tubular atrophy, 5–15% of section);
grade 2¼moderate CAN (moderate fibrosis and tubular atrophy,
16–50% of section); and grade 3¼ severe CAN (severe fibrosis and
tubular atrophy, 450% of section). Grading also included
vasculopathy with mild vasculopathy (intimal proliferation with
luminal obstruction p25%), moderate vasculopathy (luminal
obstruction 425–50%), and severe vasculopathy (luminal obstruc-
tion 450% of section). Glomerulosclerosis was analyzed by
counting sclerotic and normal glomeruli of the section and given
as the percentage of sclerotic glomeruli.
Macrophage infiltration was evaluated with the alkaline phos-
phatase antialkaline phosphatase complex (Dako, Glostrup,
Denmark) after incubation of cryostat sections (4mm) with mouse
anti-CD 68 (Serotec, Wiesbaden, Germany) and secondary rabbit
anti-mouse IgG followed by development with fast red chromogene
solution (Dako, Glostrup, Denmark). Cells with positive staining
were counted and infiltration was graded: 0¼o5 cells/field of view;
1¼ 6–25 cells/field of view; 2¼ 26–50 cells/field of view; and
3¼450 cells/field of view. At least 20 fields of view per section
and per specimen were evaluated at  400 magnification. Two
independent observers evaluated the samples in a blinded manner.
The number of proliferating cells was analyzed after incubation
of the sections with mouse anti-proliferating cell nuclear antigen
antibody (Dako, Glostrup, Denmark) followed by incubation with a
secondary horse anti-mouse antibody according to the Avidin Biotin
Complex Method and development of the color signal by peroxidase
(Vectastain elite Avidin Biotin Complex Kit; Vector Laboratories,
Burlingame, CA, USA). Tubular epithelial cells with nuclear brown
staining were counted per field of view at  100 magnification.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labelling (TUNEL) assays were performed in frozen sections
incubated with TUNEL solution42 (Roche Diagnostics, Mannheim,
Germany). After washing, sections were incubated with a rabbit
anti-digoxygenine antibody (Roche Diagnostics, Mannheim, Ger-
many). Binding was visualized using fast red chromogene solution.
Tubular epithelial cells with positive staining (red nuclei) were
counted per field of view. At least 20 fields of view per section and
per specimen were evaluated at  400 magnification. Two
independent observers evaluated the samples in a blinded manner.
Ribonuclease protection assay
Total RNA was prepared as previously described for the analysis of
mRNA levels of Bcl-2, Bax, caspase-1, and caspase-3.41 A substantial
part of renal tissue consists of cortical and medullar tubular cells (63
and 34% of relative renal tissue volume).43 Thus, a gross part of the
isolated mRNA is derived from tubular cells. Radioactive antisense
riboprobes (32P-UTP) were prepared by in vitro transcription
(RiboQuant Multi-Probe Ribonuclease Protection Assay (RPA)
System, Pharmingen, San Diego, CA, USA)35 followed by hybridiza-
tion of total RNA samples with their respective rat antisense
riboprobes according to the manufacturer’s protocol. Then, RNA
and RNase digestion and separation on a 6% polyacrylamide gel
were performed. Blots were scanned on a Fuji-BAS phosphor imager
(Fuji, Du¨sseldorf, Germany), digitized, and density of bands was
measured. The ratio between specific mRNA band densities
and housekeeping gene mRNA band (glyceraldehyde-3-phosphate
dehydrogenase) densities were calculated.
Expression of p53
Tissue samples were homogenized in lysis buffer and separated by
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Samples were transferred to Hybond-CExtra membranes (Amersham
Pharmacia Biotech, Aylesbury, UK), blocked with 5% skimmed milk
in Tris-buffered saline/0.5% Tween 20 overnight at 41C.
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Membranes were incubated with the following antibodies after
washing in Tris-buffered saline/Tween: primary antibodies –
monoclonal mouse anti human p53 (1:5000; Pharmingen, San
Diego, CA, USA), polyclonal rabbit anti b-actin (1:10 000; Sigma, St
Louis, MO, USA); secondary antibodies – goat anti-mouse
immunoglobulin G-horseradish peroxidase conjugated (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat anti-rabbit
immunoglobulin G-POD conjugated (1:5000; Vector Laboratories,
Burlingame, CA, USA). Antibodies were diluted in 5% skimmed dry
milk in Tris-buffered saline/Tween buffer. Blots were washed and
incubated with LumiLight working solution (Roche Diagnostics
GmbH, Mannheim, Germany). Density of bands was analyzed and
the ratios between p53- and b-actin bands were calculated.
Statistical analysis
Data are expressed as mean7s.e.m. Data were tested using the w2
test or Mann–Whitney U-test. Bonferroni’s method was applied to
avoid inflation of type I error in multiple testing settings. A global
P-value of o0.05 was considered significant. All tests were
performed two-tailed. Data were analyzed using the SPSS statistical
software package (v. 13.0, SPSS GmbH, Munich, Germany).
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